What Molecular Research does

Molecular Research Srl is a private Italian contract research organization (CRO) founded in 2019, headquartered in Maglie (Lecce), Italy, operating with a 1-10 employee headcount. The company applies bioinformatic analysis to identify microRNAs (miRNAs) as diagnostic and therapeutic biomarkers, with documented research focused on childhood asthma and wheezing. Its core output is a systematic review and bioinformatic platform that screened 47 published studies, identified 58 candidate miRNAs (31 upregulated, 27 downregulated), linked them to four hub genes (TNF, IL5, IL13, TLR4), and enumerated 339 potential therapeutic agents — including the approved biologics mepolizumab and benralizumab. miR-26a was characterized with 83% sensitivity and 93% specificity as a candidate diagnostic biomarker.

The firm's technology stack combines literature curation with bioinformatic toolchains (functional annotation, protein-protein interaction mapping, pathway enrichment) typical of computational biology pipelines. The business model and revenue mechanics are not disclosed in available material: there are no publicly listed products, services, or pricing, and the company website is currently under maintenance. Capital structure shows backing from the Cube Labs ecosystem (visible co-branding on the website) and a 2020 funding event involving CDP Equity and CDP Venture Capital, the Italian institutional investors. Operationally, the firm functions as an R&D-stage computational biomarker discovery operation whose customers (likely pharmaceutical/biotech sponsors of biomarker research) and contracts are not publicly identified.

Name

Molecular Research

Legal name

Molecular Research Srl

Website

https://mrct.it

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Molecular Research Srl is an Italian contract research organization founded in 2019 that applies bioinformatic analysis to discover microRNA biomarkers for diagnostics and therapeutics, with published work on childhood asthma.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)

akta.pro secondary industries

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Transcriptomics & Gene Expression Profiling Services (HLAGANAE), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH)

Keywords

• MicroRNA biomarker discovery
• Pharmaceutical research services
• Therapeutic target identification
• Bioinformatics data analysis
• Respiratory disease biomarkers

Headquarters

HQ city

Maglie

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Core offering

Molecular Research Srl is a contract research organization that conducts pharmaceutical research and applies bioinformatics analysis to identify microRNAs as diagnostic and therapeutic biomarkers. Its demonstrated research includes systematic review and biomarker analysis for childhood asthma.

Product overview

Molecular Research® Srl is a company based in Maglie, Italy (Via Mangionello, 10/12 – 73024 Maglie (LE) – Italy, VAT 04983170756). The company website was under maintenance at the time of data collection, with no active product or service offerings publicly accessible.

Differentiator

Problem solved

Functional benefit

Products and services

• MicroRNA biomarker discovery services Contract bioinformatics analysis of pharmaceutical research to identify candidate microRNAs for diagnostic and therapeutic biomarker development, with demonstrated application to childhood-asthma hub-gene and therapeutic-agent analysis.

Quantifiable outcome

• miR-26a demonstrates 83% sensitivity and 93% specificity for childhood asthma diagnosis

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators3 records

Recent moves4 records

Expansion highlights3 records

Direct peers

• Regulus Therapeutics: Clinical-stage biopharma developing microRNA-targeted therapeutics across inflammatory and metabolic indications — comparable as a specialized miRNA therapeutic platform with biomarker-to-drug translation capabilities.
• CeGaT: German genomics CRO providing transcriptomic, exome, and biomarker analysis services to pharma and academic clients — comparable as a European specialty genomics CRO with a similar R&D-services business profile.
• miRagen Therapeutics (Viridian Therapeutics): Developed microRNA-targeted therapeutics for serious diseases (now operating as Viridian Therapeutics). Comparable as a miRNA therapeutics platform that translated bioinformatic miRNA discovery into clinical assets.
• Asuragen: Molecular diagnostics company with deep expertise in microRNA biomarker assays and companion diagnostics — comparable as a small-to-mid molecular diagnostics CRO translating miRNA biology into clinical-grade tests.
• TAmiRNA: Austrian biotech specializing in microRNA biomarker discovery and diagnostics for age-related and chronic diseases — directly comparable as an SME CRO translating miRNA biomarker research into commercial diagnostic offerings.

Broad incumbents

• Cube Labs: Italian biotech venture builder that incubates and operates life-science companies. Directly comparable as the parent/incubator platform visible on Molecular Research's own website, with shared infrastructure, governance, and capital sources.
• Eurofins Genomics: Major European genomics services provider offering gene expression, sequencing, and biomarker assay services — comparable as a broad European CRO incumbent with overlapping transcriptomics/miRNA service offerings.
• QIAGEN: Global leader in molecular diagnostics and life-science sample technologies, including microRNA research products and companion diagnostics — comparable as a broad incumbent offering overlapping tools and services in the miRNA and genomic biomarker space.
• Thermo Fisher Scientific: Major life-sciences tools and CRO provider offering transcriptomics, genomics, and biomarker discovery services — comparable as a broad incumbent providing infrastructure for miRNA/gene-expression biomarker programs.

Emerging players

• Rosetta Genomics: Historically a pioneer in microRNA-based diagnostics — comparable as a niche emerging player translating microRNA biomarker research into diagnostic tests.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Molecular Research